The clinical-stage biopharmaceutical firm announced the pricing of a private placement offering to raise approximately $4 million. The company is issuing an aggregate of 2,846,975 units to a group of healthcare investors at a purchase price of $1.405 per unit.Funding The Immunotherapeutic PipelineManagement intends to deploy the net proceeds to advance its clinical pipeline. Specifically, the capital will fund clinical trials for HCW9302 and progress IND-enabling studies for its T-Cell Engager, HCW11-018b, and its second-generation immune checkpoint inhibitor, HCW11-040. The funds will also support general corporate purposes and settle outstanding debts.The capital raise provides critical liquidity; the company held cash and equivalents of $1.23 million, down from $1.95 million a year ago. The announcement halted a two-day slide where retail investors locked in profits following a massive 262% surge driven by strong first quarter financial results and an exclusive worldwide licensing agreement with Trimmune.Critical Price Levels To Watch For HCWBHCWB is in a stretched momentum phase: RSI is 84.05, signaling the move is overbought and vulnerable to pullbacks, even if the trend remains up. Price is also extremely extended versus its short-term trend gauges, trading about 350% above the 20-day SMA (61 cents) and about 424% above the 50-day SMA (52 cents). It's still only about 28% above the 200-day SMA ($2.13), making that longer-term average a key "line in the sand" if the stock starts to mean-revert.The moving-average structure is mixed: the 20-day SMA is above the 50-day SMA (bullish), but the 50-day SMA remains below the 200-day SMA (bearish longer-term backdrop). On the timeline, the stock logged a swing high in March, a swing low in April, and also tagged its 52-week low in April—so this year's rebound is happening after a deep drawdown.